{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T13:58:59Z","timestamp":1793627939672,"version":"4.5.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Invest"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/bf03261908","type":"journal-article","created":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T20:18:28Z","timestamp":1357244308000},"page":"547-553","source":"Crossref","is-referenced-by-count":3,"title":["Teriparatide Therapy for Bisphosphonate-Associated Osteonecrosis of the Jaw in an Elderly Japanese Woman with Severe Osteoporosis"],"prefix":"10.1007","volume":"32","author":[{"given":"Jun","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Yago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,13]]},"reference":[{"key":"BF03261908_CR1","first-page":"417","volume":"18","author":"L. Cavanna","year":"2007","unstructured":"Cavanna L, Bert\u00e8 R, Arcari A, et al. Osteonecrosis of the jaw: a newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature. Eur J Int Med 2007; 18: 417\u201322","journal-title":"Report of five cases and review of the literature. Eur J Int Med"},{"key":"BF03261908_CR2","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.14219\/jada.archive.2005.0110","volume":"136","author":"M.D. Melo","year":"2005","unstructured":"Melo MD, Obeld G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early detection. J Am Dent Assoc 2005; 136: 1675\u201381","journal-title":"J Am Dent Assoc"},{"key":"BF03261908_CR3","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00198-007-0384-2","volume":"18","author":"N. Yarom","year":"2007","unstructured":"Yarom N, Yahalom R, Shoshani Y, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007; 18: 1363\u201370","journal-title":"Osteoporos Int"},{"key":"BF03261908_CR4","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","volume":"24","author":"A. Badros","year":"2006","unstructured":"Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24: 945\u201352","journal-title":"J Clin Oncol"},{"key":"BF03261908_CR5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.joms.2006.10.076","volume":"65","author":"R.P. Harper","year":"2007","unstructured":"Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1\u201334)]. J Oral Maxillofac Surg 2007; 65: 573\u201380","journal-title":"J Oral Maxillofac Surg"},{"key":"BF03261908_CR6","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3899\/jrheum.081176","volume":"36","author":"A.N. Lau","year":"2009","unstructured":"Lau AN, Adachi JD. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1\u201334)] therapy. J Rheumatol 2009; 36: 1835\u20137","journal-title":"J Rheumatol"},{"key":"BF03261908_CR7","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMc1002684","volume":"363","author":"A. Cheung","year":"2010","unstructured":"Cheung A, Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 2010; 363: 2473\u20134","journal-title":"N Engl J Med"},{"key":"BF03261908_CR8","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1005361","volume":"363","author":"J.D. Bashutski","year":"2010","unstructured":"Bashutski JD, Eber RM, Kinney JS, et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 2010; 363: 2396\u2013405","journal-title":"N Engl J Med"},{"key":"BF03261908_CR9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"R.M. Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434\u201341","journal-title":"N Engl J Med"},{"key":"BF03261908_CR10","unstructured":"Lilly USA. Highlights of prescribing information [online]. Available from URL: http:\/\/pi.lilly.com [Accessed 2012 Apr 1]"},{"key":"BF03261908_CR11","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","volume":"26","author":"A.B. Hodsman","year":"2005","unstructured":"Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26: 688\u2013703","journal-title":"Endocr Rev"},{"key":"BF03261908_CR12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00198-002-1369-9","volume":"14","author":"M. Shiraki","year":"2003","unstructured":"Shiraki M, Fukunaga M, Kushida K, et al. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis. Osteoporos Int 2003; 14: 225\u201334","journal-title":"Osteoporos Int"},{"key":"BF03261908_CR13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00774-006-0706-z","volume":"24","author":"H. Kishimoto","year":"2006","unstructured":"Kishimoto H, Fukunaga M, Kushida et al. Efficacy and tolerability of once-weekly administration of 17.5mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 2006; 24: 405\u201313","journal-title":"J Bone Miner Metab"},{"key":"BF03261908_CR14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00774-010-0162-7","volume":"28","author":"T. Yoneda","year":"2010","unstructured":"Yoneda T, Hagino H, Sugimoto T, et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 2010; 28: 365\u201383","journal-title":"J Bone Miner Metab"},{"key":"BF03261908_CR15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s007740050038","volume":"16","author":"H. Orimo","year":"1998","unstructured":"Orimo H, Sugioka Y, Fukunaga M, et al. Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 1998; 16: 139\u201350","journal-title":"J Bone Miner Metab"},{"key":"BF03261908_CR16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s007740170001","volume":"19","author":"H. Orimo","year":"2001","unstructured":"Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001; 19: 331\u20137","journal-title":"J Bone Miner Metab"},{"key":"BF03261908_CR17","unstructured":"Orimo H. Japanese guideline for prevention and treatment of osteoporosis: II. Diagnosis of osteoporosis [in Japanese]. Life Science 2011: pp. 16\u201317"},{"key":"BF03261908_CR18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bone.2010.05.022","volume":"47","author":"A. Miyauchi","year":"2010","unstructured":"Miyauchi A, Matsumoto T, Sugimoto T, et al. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 2010; 47: 493\u2013502","journal-title":"Bone"},{"key":"BF03261908_CR19","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1517\/14728222.11.7.941","volume":"11","author":"S. Galluzzo","year":"2007","unstructured":"Galluzzo S, Santini D, Vincenzi et al. Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity. Expert Opin Ther Targets 2007; 11: 941\u201354","journal-title":"Expert Opin Ther Targets"},{"key":"BF03261908_CR20","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bone.2010.12.006","volume":"48","author":"M. Tsujimoto","year":"2011","unstructured":"Tsujimoto M, Chen P, Miyauchi A, et al. PINP as an aid for monitoring patients treated with teriparatide. Bone 2011; 48: 798\u2013803","journal-title":"Bone"},{"key":"BF03261908_CR21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1185\/030079908X253429","volume":"24","author":"S.K. Lim","year":"2008","unstructured":"Lim SK, Kung AW, Sompongse S, et al. Vitamin D inadequacy in postmenopausal women in Eastern Asia. Curr Med Res Opin 2008; 24: 99\u2013106","journal-title":"Curr Med Res Opin"},{"key":"BF03261908_CR22","doi-asserted-by":"crossref","unstructured":"Iwamoto J, Takeda T, Matsumoto H. Sunlight exposure is important for preventing hip fractures in patients with Alzheimer\u2019s disease, Parkinson\u2019s disease, or stroke. Acta Neurol Scand 2011. Epub","DOI":"10.1111\/j.1600-0404.2011.01555.x"},{"key":"BF03261908_CR23","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1212\/01.WNL.0000078892.24356.90","volume":"61","author":"Y. Sato","year":"2003","unstructured":"Sato Y, Metoki N, Iwamoto J, et al. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in stroke patients. Neurology 2003; 61: 338\u201342","journal-title":"Neurology"},{"key":"BF03261908_CR24","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1359\/JBMR.050402","volume":"20","author":"Y. Sato","year":"2005","unstructured":"Sato Y, Iwamoto J, Kanoko T, et al. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in hospitalized, elderly women with Alzheimer\u2019s disease: a randomized controlled trial. J Bone Miner Res 2005; 20: 1327\u201333","journal-title":"J Bone Miner Res"},{"key":"BF03261908_CR25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.parkreldis.2010.10.008","volume":"17","author":"Y. Sato","year":"2011","unstructured":"Sato Y, Iwamoto J, Honda Y. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson\u2019s disease. Parkinsonism Relat Disord 2011; 17: 22\u20136","journal-title":"Parkinsonism Relat Disord"},{"key":"BF03261908_CR26","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1210\/jc.2007-0239","volume":"92","author":"B. Dawson-Hughes","year":"2007","unstructured":"Dawson-Hughes B, Chen P, Krege JH. Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. J Clin Endocrinol Metab 2007; 92: 4630\u20136","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03261908_CR27","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","volume":"164","author":"R. Lindsay","year":"2004","unstructured":"Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004; 164: 2024\u201330","journal-title":"Arch Intern Med"},{"key":"BF03261908_CR28","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1359\/JBMR.050501","volume":"20","author":"R. Prince","year":"2005","unstructured":"Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005; 20: 1507\u201313","journal-title":"J Bone Miner Res"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261908.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03261908\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T18:27:11Z","timestamp":1562524031000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03261908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["BF03261908"],"URL":"https:\/\/doi.org\/10.1007\/bf03261908","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}